
Statins reduced risk of colorectal cancer in meta-analysis
10 December 2020Findings from a recent study showed that people who regula [...]
READ MORECOVID-19 and Colorectal Cancer Get The Facts
Today, Wednesday September 30th, is World Metastatic Colorectal Cancer Day – a day dedicated to raising awareness of the most advanced form of colorectal cancer, known as metastatic colorectal cancer (mCRC); this is when the cancer has spread to other parts of the body, such as the liver or lungs.
#BowelCancerAustralia, #ColonCancerAlliance, #ColorectalCancerCanada, #BowelCancerUK, and #FightCRC have come together today to raise awareness on biomarkers as predictive indicators of disease and response to targeted therapies such as immunotherapy.
Colorectal cancer is expected to be the third most commonly diagnosed cancer in Canada, such that 26,900 Canadians will be diagnosed with colorectal cancer in 2020.
There have been considerable advances in the treatment of mCRC over the past 15 years, yet the prognosis of patients with mCRC still remains poor. For this reason, more effective therapeutic strategies are necessary for metastatic disease. The inclusion of biomarkers into therapy selection for patients with metastatic colorectal cancer can significantly improve outcomes.
Biomarker testing for metastatic colorectal cancer can personalize therapy for patients to optimize outcomes. For instance, testing for biomarkers such as RAS, MSI-H/dMMR BRAF V600E, and NTRK can guide patient selection for specific immunotherapy drugs.
Immunotherapy has revolutionized cancer therapy, and specifically immune checkpoint inhibitor (ICI) therapy has rapidly changed the treatment landscape in oncology. These include drugs such as: Cetuximab, Panitumumab, Pembrolizumab, Nivolumab, Ipilimumab, Vemurafenib, and Larotrectinib. “The development of biomarkers contributes to revealing the therapeutic mechanisms of ICIs and the interaction mechanisms between tumor and host immunity, achieving decision-making of individualized anti-tumor immunotherapy, monitoring efficacy and disease development, guiding clinical trial design, as well as for further understanding of drug resistance mechanisms and tumor prognosis”1 Improvements in the survival of patients with mCRC will be made possible with the identification of new predictive molecular biomarkers and their evaluation through clinical trials.
References: 1. https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-020-00209-0
10 December 2020Findings from a recent study showed that people who regula [...]
READ MORE22 December 2020 Hepatic Artery Infusion (HAI) chemotherapy is sometime [...]
READ MORENovember 2020 Findings from a recent study conducted by the Mayo Clinic [...]
READ MOREThe non-surgical management or “watch-and-wait” approach for rectal c [...]
READ MOREThe incidence of colorectal cancer (CRC) is rising among young adults, who [...]
READ MOREOpportunity to Investigate the Microbiome’s Impact on Science and Treatmen [...]
READ MORENew findings from a study conducted at the University of Sheffield in [...]
READ MORESexuality and relationships during and after cancer is extremely impor [...]
READ MOREChadwick Boseman’s death from colorectal cancer (CRC) at age 43 was a shoc [...]
READ MOREDr. Heinz-Josef Lenz, MD, discusses optimal sequencing strategies for [...]
READ MOREThe European Society for Medical Oncology ESMO Virtual Congress 2020 t [...]
READ MOREJesse Fishman is a 17-year-old hockey player, currently playing for the Ki [...]
READ MORE12 August 2020 Recent findings from a Swedish cohort study found that p [...]
READ MOREIt was the day of the lockdown. My family doctor called. “The colorectal c [...]
READ MOREFill out the survey! The world was shocked late last week as we learned a [...]
READ MOREPrevious data have shown that certain species of intestinal bacteria not o [...]
READ MOREAs we transition into autumn, take a moment to appreciate the seasonal pro [...]
READ MOREThe COVID-19 pandemic has presented countless new challenges in cancer car [...]
READ MOREThe COVID-19 pandemic situation is constantly evolving. Canada is slowly r [...]
READ MOREResults of several new studies provide important perspectives on the use o [...]
READ MOREIn the past two years, findings from important clinical trials are shaping [...]
READ MOREHold the Date! On behalf of Colorectal Cancer Canada (CCC), you are cordi [...]
READ MOREWhat is Lynch Syndrome? Lynch syndrome is a genetically inherited conditi [...]
READ MORECoronavirus has taken the world by storm since the beginning of 2020, and [...]
READ MORETo ensure the health and safety of our participants, volunteers, staff and [...]
READ MOREThe American Society of Clinical Oncology (ASCO) held its annual meeting a [...]
READ MOREIn just a few months, coronavirus (COVID-19) has transformed our lives. De [...]
READ MOREIt has been known for millennia that what we eat can be powerful medicine [...]
READ MOREThe last few decades have seen important advances in colorectal cancer tre [...]
READ MORECo-leads of Push For Your Tush Ottawa share their connection to the cause [...]
READ MOREThe Centre de recherche of the Centre hospitalier universitaire de Sherbro [...]
READ MOREOn June 24, 2019, colorectal cancer screening in Ontario is changing to th [...]
READ MOREToday we remember Dr. Henry Lynch, esteemed researcher and father of hered [...]
READ MOREOn Tuesday, July 16, Colorectal Cancer Canada (CCC) held our third annual [...]
READ MOREResearchers with the World Health Organization confirm increased rates of [...]
READ MORELast Thursday and Friday, Morgan Kennedy, CCC’s Never Too Young Program Ma [...]
READ MOREColorectal Cancer Canada (CCC) is proud to announce the publication of the [...]
READ MOREToday, the Giant Colon Tour stopped at the University of Montreal Hospital [...]
READ MOREMost people do not know that cancer is the number one cause of death among [...]
READ MOREMarch is Colorectal Cancer Awareness Month! Colorectal cancer may touch yo [...]
READ MORE